AMICUS THERAPEUTICS, INC. — Major Shareholding Notification 2012

Feb 14, 2012

EFPlaceholder UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Rule 13d-102)

Information To Be Included In Statements Filed Pursuant

To § 240.13d-1(b), (c), and (d) and Amendments Thereto Filed

Pursuant To § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 2) *

Amicus Therapeautics, Inc.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

03152W109

(CUSIP Number)

December 31, 2011

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

• The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 03152W109 SCHEDULE 13G Page 2 of 11 Pages

1	NAMES OF REPORTING PERSONS Quaker BioVentures, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER* 0
	6	SHARED VOTING POWER 1,064,822
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,064,822
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,064,822
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9** 3.1%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

• All share numbers and ownership percentages reported herein are as of December 31, 2011.

** All ownership percentages reported herein are based on 34,654,206 outstanding shares of the Issuer’s common stock as of October 26, 2011.

CUSIP No. 03152W109 SCHEDULE 13G Page 3 of 11 Pages

1	NAMES OF REPORTING PERSONS Garden State Life Sciences Ventures Fund, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER* 0
	6	SHARED VOTING POWER 354,940
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 354,940
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 354,940
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9** 1.0%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

• All share numbers and ownership percentages reported herein are as of December 31, 2011.

** All ownership percentages reported herein are based on 34,654,206 outstanding shares of the Issuer’s common stock as of October 26, 2011.

CUSIP No. 03152W109 SCHEDULE 13G Page 4 of 11 Pages

1	NAMES OF REPORTING PERSONS Quaker BioVentures Capital, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER* 0
	6	SHARED VOTING POWER 1,419,762
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 1,419,762
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,419,762
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9** 4.1%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

• All share numbers and ownership percentages reported herein are as of December 31, 2011.

** All ownership percentages reported herein are based on 34,654,206 outstanding shares of the Issuer’s common stock as of October 26, 2011.

CUSIP No. 03152W109 SCHEDULE 13G Page 5 of 11 Pages

1	NAMES OF REPORTING PERSONS Quaker BioVentures Capital, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) x (b) o
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER* 10,000
	6	SHARED VOTING POWER 1,419,762
	7	SOLE DISPOSITIVE POWER 10,000
	8	SHARED DISPOSITIVE POWER 1,419,762
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,429,762
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9** 4.1%
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

• All share numbers and ownership percentages reported herein are as of December 31, 2011.

** All ownership percentages reported herein are based on 34,654,206 outstanding shares of the Issuer’s common stock as of October 26, 2011.

CUSIP No. 03152W109 SCHEDULE 13G Page 6 of 11 Pages

Item 1(a)	Name of Issuer: Amicus Therapeautics, Inc.
Item 1(b)	Address of Issuer’s Principal Executive Offices: 6 Cedar Brook Drive Cranbury, New Jersey 08512
Item 2(a)	Name of Person Filing: Quaker BioVentures, L.P. – Delaware Garden State Life Sciences Ventures Fund, L.P. – Delaware Quaker BioVentures Capital, L.P. – Delaware Quaker BioVentures Capital, LLC – Delaware
Item 2(b)	Address of Principal Business Office or, if none, Residence: The address of the principal business office of each of the Reporting Persons is 2929 Arch Street, Cira Centre, Philadelphia, PA 19104-2868.
Item 2(c)	Citizenship: Quaker BioVentures, L.P. – Delaware Garden State Life Sciences Ventures Fund, L.P. – Delaware Quaker BioVentures Capital, L.P. – Delaware Quaker BioVentures Capital, LLC – Delaware
Item 2(d)	Title of Class of Securities: Common Stock, $0.01 par value per share
Item 2(e)	CUSIP Number: 03152W109
Item 3	Not applicable.
Item 4	Ownership: Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned:
	Quaker BioVentures, L.P. – 1,064,822 Garden State Life Sciences Ventures Fund, L.P. – 354,940 Quaker BioVentures Capital, L.P. – 1,419,762 Quaker BioVentures Capital, LLC – 1,429,762

CUSIP No. 03152W109 SCHEDULE 13G Page 7 of 11 Pages

	(b) Percent of class: Quaker BioVentures, L.P. – 3.1% Garden State Life Sciences Ventures Fund, L.P. – 1.0% Quaker BioVentures Capital, L.P. – 4.1% Quaker BioVentures Capital, LLC – 4.1%
	(c) Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote Quaker BioVentures, L.P. – 0 Garden State Life Sciences Ventures Fund, L.P. – 0 Quaker BioVentures Capital, L.P. – 0 Quaker BioVentures Capital, LLC –10,000
	(ii) Shared power to vote or to direct the vote Quaker BioVentures, L.P. – 1,064,822 Garden State Life Sciences Ventures Fund, L.P. – 354,940 Quaker BioVentures Capital, L.P. – 1,419,762 Quaker BioVentures Capital, LLC – 1,419,762
	(iii) Sole power to dispose or to direct the disposition of Quaker BioVentures, L.P. – 0 Garden State Life Sciences Ventures Fund, L.P. – 0 Quaker BioVentures Capital, L.P. – 0 Quaker BioVentures Capital, LLC – 10,000
	(iv) Shared power to dispose or to direct the disposition of Quaker BioVentures, L.P. – 1,064,822 Garden State Life Sciences Ventures Fund, L.P. – 354,940 Quaker BioVentures Capital, L.P. – 1,419,762 Quaker BioVentures Capital, LLC – 1,419,762
	Quaker BioVentures Capital, L.P. is the general partner of each of Quaker BioVentures, L.P. and Garden State Life Sciences Ventures Fund, L.P. Quaker BioVentures Capital, LLC is the general partner of Quaker BioVentures Capital, L.P.
Item 5	Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following box. x

CUSIP No. 03152W109 SCHEDULE 13G Page 8 of 11 Pages

Item 6	Ownership of More than Five Percent on Behalf of Another Person. Not applicable.
Item 7	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.
Item 8	Identification and Classification of Members of the Group. Each of the Reporting Persons may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended.
Item 9	Notice of Dissolution of Group. Not applicable.
Item 10	Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 03152W109 SCHEDULE 13G Page 9 of 11 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2012
GARDEN STATE LIFE SCIENCES VENTURES FUND, L.P. By: BioAdvance GP I, L.P., its general partner By: BioAdvance GP II, Inc., its general partner /s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President
QUAKER BIOVENTURES CAPITAL, L.P. By: Quaker BioVentures Capital, LLC, its general partner /s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President
QUAKER BIOVENTURES CAPITAL, LLC /s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

CUSIP No. 03152W109 SCHEDULE 13G Page 10 of 11 Pages

Exhibit 1

JOINT FILING AGREEMENT

Joint Filing Agreement, dated as of February 14, 2012, is by and among Quaker BioVentures, L.P., Garden State Life Sciences Ventures Fund, L.P., Quaker BioVentures Capital, L.P., Quaker BioVentures Capital, LLC and BioAdvance GP I, L.P. (the “Quaker Filers”).

Each of the Quaker Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G with respect to shares of Common Stock, par value $0.001 per share, of Amicus Therapeautics, Inc. beneficially owned by it from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the Quaker Filers hereby agree to be responsible for the timely filing of the Schedule 13G and any amendments thereto on behalf of the Quaker Filers, and for the completeness and accuracy of the information concerning itself contained therein. Each of the Quaker Filers hereby further agree to file this Joint Filing Agreement as an exhibit to the statement and each such amendment, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Quaker Filers upon one week’s prior written notice or such lesser period of notice as the Quaker Filers may mutually agree.

Executed and delivered as of the date first above written.

Date: February 14, 2012
GARDEN STATE LIFE SCIENCES VENTURES FUND, L.P. By: BioAdvance GP I, L.P., its general partner By: BioAdvance GP II, Inc., its general partner /s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President
QUAKER BIOVENTURES CAPITAL, L.P. By: Quaker BioVentures Capital, LLC, its general partner /s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

CUSIP No. 03152W109 SCHEDULE 13G Page 11 of 11 Pages

QUAKER BIOVENTURES CAPITAL, LLC /s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President